Premium
Intrathecal interferon in subacute sclerosing panencephalitis
Author(s) -
Maimone D.,
Grimaldi L. M. E.,
Incorpora G.,
Biondi R.,
Sofia V.,
Mancuso G. Russo,
Siciliano L.,
Ruscica M.,
Pavone L.
Publication year - 1988
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1988.tb03639.x
Subject(s) - subacute sclerosing panencephalitis , intrathecal , medicine , intravenous immunoglobulins , gastroenterology , interferon , anesthesia , antibody , immunology , measles , measles virus , vaccination
‐ Three patients at Stage II of subacute sclerosing panencephalitis (SSPE) were treated with semipurified alpha‐interferon (IFN) using different combinations of intrathecal and intravenous routes: 1 × 10 6 IU of alpha‐IFN were given every other day up to a total of 15 × 10 6 IU. Transient improvement of neurological symptoms and electroencephalogram were noted in all 3, while cognitive function slightly improved in 2 of them. Clinical benefits gradually disappeared 2 to 6 months after cessation of IFN. Intrathecal antibody production did not change substantially, but CSF Leu 3a/Leu 2a ratio appeared to increase. No significant side effects were observed, except for a mild meningeal inflammatory reaction after each intrathecal administration of IFN.